Development of a global network of induced pluripotent stem cell haplobanks

it was suggested that such cells would be ideal for patient-specific cell therapy. While clinical-grade autologous cells could be produced, this seems unlikely to occur on a large scale because of the costs and time that are involved, at least with pres -ent protocols. Rather it has been suggested by several groups